Connect your AI

Incyte INCY Business Segments — Asset impairment and related disposal costs

Similar metrics at other companies

RNGRReportable Segment — Impairment of assets

$0—

CHGGReportable Segment — Impairment expense

$0-100%

PACBReportable Segment — Impairment Charges

$0-100%

GOReportable Segment — Asset Impairment Charges, Excluding Goodwill Impairment

$28.45M—

CNXCReportable Segment — Impairment Charges

$381.93M—

LAWReportable Segment — Impairment Charges

$0-100%

Other financials

Income statement

Revenue$1.7B+37.7%

Gross profit$1.6B+38.0%

Operating income$697.9M+31.6%

Net income$585.6M+44.6%

EPS (diluted)$2.81+37.7%

Balance sheet

Cash & equivalents$4.0B+104%

Total debt$38.3M-9.8%

Total equity$6.3B+52.1%

Total assets$7.9B+35.2%

Cash flow

Operating cash flow$507.7M+1,035%

CapEx$1.6M-43.5%

Free cash flow$509.3M+1,069%

Valuation

Market cap$25.76B+70.1%

Enterprise value$21.82B+64.9%

P/E16×-1.4×

P/S4.4×+1.1×

Profitability

Gross margin92.6%-0.3pp

Operating margin30.6%+4.8pp

Net margin27.7%+8.7pp

FCF margin34%+12.3pp

Returns & leverage

Return on equity30.7%+6.4pp

Debt / equity0×0.0×

Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's business segments — asset impairment and related disposal costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Incyte's business segments — asset impairment and related disposal costs?: Incyte (INCY) reported business segments — asset impairment and related disposal costs of $0 in Q2 2026.
What does business segments — asset impairment and related disposal costs mean?: This represents non-cash charges taken when the carrying value of an asset, such as a drug program or intangible asset, exceeds its fair value. It signals a reassessment of the future economic benefit of a specific project or acquisition.